New in vitro screening model for the discovery of antileukemic anticancer agents

Cancer Investigation

Volumn 14, Issue 2, 1996, Pages 124-141

  Valeriote, Frederick ^b   Corbett, Thomas ^b   Edelstein, Mark ^b   Baker, Laurence ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ALANOSINE; ANTINEOPLASTIC AGENT; BACTOBOLIN; BERBERINE; BOUVARDIN; BRUCEANTIN; CHARTREUSIN; CHLOROZOTOCIN; CHRYSOMYCIN A; CHRYSOMYCIN B; CINERUBIN B; COMBRETASTATIN A1; DEACETYLCOLCHICINE; DEOXYNARCICLASINE; ECHINOMYCIN; HYDROXYELLIPTICINIUM; KIDAMYCIN; MULTIGILIN; NEW DRUG; NOGAMYCIN; NYBOMYCIN; PACLITAXEL; PANCRATISTATIN; PELTATIN A; PIPERAZINEDIONE; SANGIVAMYCIN; STERIGMATOCYSTIN; TRIMETREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; USNIC ACID; VERRUCARIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; DRUG SCREENING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL LINE;

EID: 0029944497     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609018888     Document Type: Review

References (32)

1. Driscoll JS: The preclinical new drag research program of the National Cancer Institute. Cancer Treat Rep 68:63-76, 1984.
2. Corbett T, Valeriote F, Baker L: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5:3-20, 1987.
3. Schabel FM Jr, Skipper HE, Trader MW, Laster WR, Griswold DP Jr, Corbett TH: Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67:905-922, 1983.
4. Skipper H: Drug evaluation in experimental tumor systems: Potential and limitations in 1961. Cancer Chemother Rep 16:11-19, 1962.
5. Hirschberg E: Patterns of response of animal tumors to anticancer agents: A systematic analysis of the literature in experimental cancer chemotherapy - 1945-1958. Cancer Res 23:521-1084, 1963.
6. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Sehabel FM Jr: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660-2680, 1977.
7. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/c) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62:1471-1488, 1978.
8. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr: Induction and chemotherapeutic response of two transplan table ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44:717-726, 1984.
9. Corbett TH, Valeriote FA: Rodent models in experimental chemotherapy. In: The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, edited by RF Kallman, New York, Pergamon Press, 1987, Chapter 50, pp 233-247.
10. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ: Cell culture screen, KB protocol 1,600. Cancer Chemother Rep 3:17, 1972.
11. Shoemaker RH, Abbott BJ, MacDonald MM, Mayo JG, Venditti JM, Wolpert-DeFilippes MK: Use of the KB cell line for in vitro cytotoxicity assays. Cancer Treat Rep 67:97, 1983.
12. Corbett TH, Wozniak A, Gerpheide S, Hanka L: A selective twotumor soft agar assay for drug discovery. In: In Vitro and In Vivo Models for Detection of New Antitumor Drugs, Proc. 14th International Congress of Chemotherapy, edited by LJ Hanka, T Kondo, RJ White, Tokyo, University of Tokyo Press, 1986, pp 5-14.
13. Corbett TH, Polin L, Wozniak AJ, Bissery M, LoRusso PM, Valeriote FA: The use of multiple-tumor-soft-agar-disk-diffusionassay to detect agents with selective solid tumor activity. Proc Am Assoc Cancer Res 29:533-534, 1988.
14. Mucci-LoRusso P, Polin L, Biernat LA, Valeriote FA, Corbett TH: Activity of detalliptinium (NSC-311152) against solid tumors of mice. Invest New Drugs 8:253-261, 1990.
15. Corbett TH, Valeriote FA, Polin L, et al: Discovery of solid tumor active agents using a soft-agar-colony-formation-disk-diffusionassay. In: Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, edited by F Valeriote, T Corbett, L Baker, Boston, Kluwer Academic Publishers, 1992, pp 35-87.
16. Shoemaker RH, Wolpert-DeFilippes MK, Kern.DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, VonHoff DD: Application of a human tumor colony forming assay to new drug screening. Cancer Res 45:2145-2153, 1985.
17. Salmon SE, Hamburger AW, Soehnlen B, et al: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321-1327, 1978.
18. Alberts DS, Salmon SE, Chen HSG, Moon TE, Young L, Surwit EA: Pharmacologic studies of anti cancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:253-264, 1981.
19. VonHoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF: Prospective clinical trial of a human tumor cloning system. Cancer Res 3:1926-1931, 1983.
20. Bradner WT, Pindell MH: Myeloid leukemia C1498 as a screen for cancer chemotherapeutic agents. Cancer Res 2(Part2):375-390, 1966.
21. Gallagher R, Collins S, Trujillo J, et al: Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54:713-733, 1979.
22. Lozzio C, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45:321-334, 1975.
23. Martin P, Papayannopoulou T: HEL cells: A new human erythroleukemia cell line with spontaneous and induced globin expression. Science 216:1233-1235, 1982.
24. Tsuchiya S, Yamabe M, Yamaguchi Y, et al: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26:171-176, 1980.
25. Cavanaugh PF, Mattes K: Large scale anticancer drug screening at Sterling Drug Inc. In: Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, edited by F Valeriote, T Corbett, L Baker, Boston, Kluwer Academic Publishers, 1992, pp 197-204.
26. Edelstein M, Valeriote F, Vietti T: Cellular quantitation of in vivo effects of 1-β-D-arabinofuranosylcytosine on leukemia L1210. J Natl Cancer Inst 58:941-947, 1977.
27. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep (3)2, 1972.
28. Interpretive Chart for Coding Used in DR&D Screening Data Summaries. Revision 9/84. Information Technology Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD.
29. Boyd MR, Paull KD, Rubenstein LR: Data display and analysis strategies for the NCI disease-oriented in vitro antitumor drug screen. In: Anticancer Drug Discovery and Development, edited by F Valeriote, T Corbett, L Baker, Boston, Kluwer Academic Publishers, 1991.
30. Johnson RK: Screening methods in antineoplastic drug discovery. J Natl Cancer Inst 82:1082-1083, 1990.
31. Chabner BA: In defense of cell-line screening. J Natl Cancer Inst 82:1083-1085, 1990.
32. Boyd MR: Status of the NCI preclinical antitumor drug discovery screen. In: Cancer: Principles and Practice of Oncology Updates. Vol 3. edited by VT De Vita Jr, S Hellman, SA Rosenberg, Philadelphia, JB Lippincott, 1989, pp 1-12.